Treace Medical Q3 revenue falls but slightly beats expectations
Overview
US bunion surgery device maker's Q3 revenue fell 4% yr/yr, slightly beating analyst expectations
Adjusted EBITDA turned positive in Q3, improving from a loss a year earlier
Revenue decline driven by shift to lower-priced minimally invasive products and lower kit volumes
Outlook
Treace Medical sees 2026 revenue at $206 mln to $210 mln, down from prior $204 mln-$212 mln range
Treace Medical reiterates expectation for 2026 cash usage to fall about 50% from 2025
Result Drivers
PRODUCT MIX SHIFT - Co said revenue declined mainly due to greater sales of lower-priced minimally invasive products and lower volume of bunion procedure kits
INCREASED ADOPTION - Co reported higher adoption of expanded bunion portfolio, with about 45% of Lapiplasty surgeon users now using one or more new systems, up from 40% in Q2
EXPENSE REDUCTION - Operating expenses fell 10% yr/yr, attributed to targeted expense reduction initiatives
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Beat* | $48.25 mln | $47.80 mln (5 Analysts) |
Q3 Loss Per Share | $0.19 | ||
Q3 Gross Margin | 79.50% | ||
Q3 Gross Profit | $38.35 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Reuters Recommended Reads
Nov 5 - Apyx Medical Q3 revenue beats estimates on AYON system demand
Nov 5 - Globus Medical Q3 sales fall 0.7%, miss estimates; adjusted EPS beats
Nov 3 - RxSight Q3 revenue falls on competitive pressures
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)